FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Biotechnology Practice > IT Operating Model And Service Management

IT Operating Model And Service Management

Service Line: Operations

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]

Capability: IT Operating Model And Service Management

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with IT Operating Model And Service Management in the context of Biotechnology. Leaders across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators needed a fit-for-purpose IT operating model, ITIL processes, and a service catalog—backed by SLAs/OLAs, DevSecOps practices, and vendor management—to improve service quality, delivery speed, and GxP compliance across ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, serialization/EPCIS, safety (E2B), and data/analytics platforms. The diagnostic surfaced structural gaps and pain points:

  • Fragmented operating model and unclear accountabilities
    • IT and Quality roles overlapped for change, validation (CSV/CSA), and periodic reviews; functional teams bypassed central IT with shadow tools and direct vendor escalations. There was no unified RACI for incident, problem, change, release, or request fulfillment. CAB/CCB decisions were inconsistent, and production changes occurred outside windows needed by CMC and clinical operations.
  • Missing or immature ITIL v4 processes
    • Incident and major incident management lacked runbooks; handoffs between L1/L2/L3 were unclear; MTTR and first contact resolution were not measured. Problem management and root cause analysis were ad hoc; knowledge management was tribal. Change enablement lacked risk classification and pre-approved standard changes; deployment success and rollback readiness were not tracked.
  • Service catalog gaps and poor request experience
    • No formal catalog existed for core services (e.g., CTMS site onboarding, eTMF access, ERP role requests, MES recipe updates, LIMS test method setup, QMS workflow changes, serialization/EPCIS connection); request models varied by system; SLA/OLA expectations were undefined; status transparency was low.
  • DevSecOps and validation friction
    • CI/CD pipelines, infrastructure-as-code, and automated testing existed in pockets; validation documentation (CSA) was not aligned to modern SDLC practices; developers and site support teams avoided pipeline use due to approval latency and unclear evidence standards. Emergency changes increased, raising Part 11/Annex 11 risk.
  • Vendor and MSP sprawl with weak QBR discipline
    • Multiple managed service providers supported overlapping apps and layers (cloud, network, apps) without a unifying service integration and management (SIAM) model. SOWs lacked objective evidence of completion and service credits; QBRs were status-only, not KPI-driven; escalation ladders and run/operate RACIs were unclear.
  • OT/IT support boundaries and plant realities
    • Manufacturing sites lacked clear incident flows for MES/eBR, historian, PLC/SCADA, and LIMS; Purdue Model segmentation and change windows were inconsistently enforced; plant maintenance overlapped with IT patching and change schedules, creating production risk.
  • Data integrity and audit readiness risk
    • Audit trail review cadence (LIMS, MES, CTMS, eTMF) was not tied to service processes; backup/restore and DR test evidence was not captured through ITSM flows; CAPA linkage from incidents and problems to Quality systems was inconsistent; inspection requests were difficult to fulfill due to missing lineage and document control.
  • Metrics and cost transparency absent
    • Foundational KPIs (MTTD/MTTR, incident reopen rate, change success rate, % emergency changes, deployment frequency, lead time for change, backlog aging) were not tracked. FinOps cost allocation was missing for run/operate services; lack of unit economics impaired trade-offs and vendor accountability.
  • User experience and adoption challenges
    • Scientists, clinical users, and site operators perceived IT as a bottleneck; request turnaround times were unpredictable; training content was not tailored; the service desk had limited domain knowledge for GxP tools and site processes.

Observed signals included: elevated emergency change rates impacting MES/LIMS and CTMS/EDC; recurring TMF completeness/timeliness/accuracy shortfalls; delayed PPQ/CPV analytics due to unresolved incidents; high variance in deployment success; frequent audit observations referencing audit trail reviews and backup/restore evidence; vendor finger-pointing during outages; and budget overruns from unplanned services and change orders. Executives asked for a pragmatic IT operating model, ITIL process design, and DevSecOps adoption aligned to GxP and milestone cadence—IND/CTA, PoC, PPQ/CPV, BLA/MAA, and launch.

2) Project Objective

The primary objective focused on designing and implementing a biotech-fit IT operating model and service management framework—ITIL v4 processes, service catalog with SLAs/OLAs, DevSecOps practices, and vendor management—to improve service quality, delivery speed, and compliance across GxP and enterprise systems while protecting critical milestones.

Secondary objectives included:

  • Standing up incident, major incident, problem, change, release, request, knowledge, and configuration management with a CMDB and runbook library tailored to ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, serialization/EPCIS, and safety (E2B).
  • Defining a service catalog and request models with role-based workflows (RBAC/ABAC), JML automation, and transparent SLAs/OLAs.
  • Implementing DevSecOps and SRE practices (CI/CD, IaC, automated testing, observability) with CSA-aligned validation to reduce change lead time and improve deployment success.
  • Establishing a SIAM-aligned vendor operating model with QBRs, KPI scorecards, service credits/penalties, and clear escalation ladders.
  • Embedding Part 11/Annex 11/CSA controls (audit trail review cadence, time sync evidence, e-signature, backup/restore, periodic reviews) into ITSM workflows with linkages to eQMS for CAPA.
  • Integrating OT/IT support for plants with Purdue Model segmentation, change windows, and site-aware incident flows.
  • Launching dashboards for service and delivery KPIs plus cost/FinOps views; aligning governance to portfolio and Quality forums.

3) Methodology and Approach

Workstream 1: Operating Model Blueprint and RACI

We defined how IT, Quality, and functional teams collaborate to deliver and assure services.

  • Defined service ownership and product ownership per domain (ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, data/analytics, network/cloud, serialization/EPCIS, safety/E2B).
  • Established a unified RACI mapping for incident/major incident, problem, change, release, request, knowledge, and configuration management; clarified CAB/CCB vs. ARB/Design Authority roles and escalation ladders to Quality and executive sponsors.
  • Designed a tiered support model (L1 Service Desk, L2 Application/Platform, L3 Vendor/Product) with domain-specific queues and knowledge bases; formalized OT/IT split roles at plants and interface points for MES/LIMS/historian/PLC/SCADA.

Workstream 2: ITIL v4 Process Design and SOPs

We authored practical, audit-ready processes tuned to biotech systems and validation needs.

  • Incident and major incident management: priority matrix and SLOs; standardized triage and comms; blameless postmortems; bridge procedures for critical GxP systems; integration to SIEM and EDR/XDR; ticket templates capturing Part 11/Annex 11 relevant evidence (timestamps, users, audit references).
  • Problem management: root cause analysis methods (5 Whys, Fishbone, Barrier Analysis) with CAPA linkage; problem review board cadence; known error database with workaround and fix documentation.
  • Change enablement: risk classification (standard/normal/emergency); pre-approved standard changes; change risk model referencing validation (CSA) scope; approvals (CAB/CCB) and blackout windows aligned to PPQ/clinical operations; change success/rollback tracking; e-signature capture where required.
  • Release management: release calendar and cutover runbooks; non-prod to prod promotion criteria; automated deployment verification; release readiness and rollback criteria; post-release KPI review.
  • Request management: catalog item design and request models with RBAC/ABAC and segregation of duties; SLA timers and automated provisioning where feasible (e.g., CTMS/eTMF access, LIMS role changes, ERP new supplier setup, MES recipe deployment).
  • Knowledge management: knowledge-centered support (KCS) practices; SOP/WI mapping to KBs; multimedia runbooks for labs and plants; inspection-ready knowledge references.
  • Configuration management: CMDB data model with CIs for applications, interfaces (ERP–MES–LIMS–QMS; CTMS–EDC–eTMF; EPCIS; E2B), environments, OT assets; discovery integrations; CI-to-change linkage to improve impact assessment.

Workstream 3: Service Catalog, SLAs/OLAs, and JML Automation

We made services transparent, fast, and compliant.

  • Published a business-centric catalog with categories (Access & Accounts, Applications, Data & Analytics, Plant & OT, Clinical Study Support, Quality & Validation, Vendor/Partner Connectivity, Security & Privacy) and standardized items (e.g., “CTMS site onboarding,” “eTMF role change,” “ERP SoD role update,” “MES recipe promotion,” “LIMS method setup,” “EPCIS connection test,” “E2B gateway verification”).
  • Defined SLAs/OLAs with clear targets (first response, resolution/fulfillment), working calendars, and escalation thresholds; aligned OLAs between internal teams and vendors.
  • Automated JML: integrated HRIS to ITSM (e.g., ServiceNow/Jira Service Management) and IdP for SCIM-based provisioning; introduced SoD checks and e-signature approvals; automated deprovisioning and quarterly access reviews with audit evidence packets.

Workstream 4: DevSecOps & SRE with CSA Validation

We accelerated delivery while meeting GxP assurance.

  • Shifted to pipeline-driven delivery (CI/CD) for apps and infra (IaC): integrated static analysis (SAST/SCA), dynamic testing (DAST), secrets scanning, SBOM collection; enforced peer review and approval gates integrated with change enablement.
  • Authored CSA validation approach for pipelines and product changes: intended use/critical functions, risk-based testing, supplier leverage, and periodic review; generated “validation by design” artifacts automatically from pipelines.
  • Introduced SRE practices: SLOs and error budgets; observability standards (logs, metrics, traces); runbooks and auto-remediation; capacity and performance dashboards for MES–LIMS, CTMS–eTMF, and serialization.

Workstream 5: Vendor Operating Model and SIAM

We unified MSPs and SaaS providers under one playbook and accountability model.

  • Defined service integration and management roles: single service desk experience; incident correlation and vendor swarm model; unified major incident process; shared CMDB and knowledge.
  • Introduced KPI scorecards and QBRs: incident SLA adherence, MTTR, change success rate, deployment frequency, % emergency changes, backlog aging, interface error rates, security patch SLAs; service credits/penalties and corrective action plans for misses.
  • Codified escalation ladders and executive governance; aligned SOWs to outcomes with objective evidence of completion and milestone payments for integration tests (EPCIS, E2B) and validation deliverables.

Workstream 6: OT/IT Support Model for Plants

We tailored service management to manufacturing realities.

  • Created plant-specific incident paths and on-call rotations; defined site-level runbooks for MES/eBR, historian, PLC/SCADA, LIMS interfaces, and environmental monitoring; set time sync (NTP) checks and audit trail review cadences into site routines.
  • Established change windows and maintenance calendars coordinated with production and validation; standardized recipe promotion and method deployment; linked site deviations to problem management and CAPA.

Workstream 7: Compliance by Design—Part 11/Annex 11 and Data Integrity

We embedded inspection readiness into everyday operations.

  • Mapped incident, change, and request workflows to capture audit trail review evidence, e-signature usage, and backup/restore results; created periodic review schedules with ITSM-generated audit packages.
  • Integrated ITSM with eQMS for CAPA initiation from problems and major incidents; aligned validation/periodic review with change enablement; prepared inspection storyboards (service processes, evidence samples, roles, and decisions).

Workstream 8: Metrics, Dashboards, and FinOps

We made performance and cost visible and actionable.

  • KPIs: incident volume by priority, MTTD/MTTR, major incident frequency, first contact resolution, reopen rate; change success rate, deployment frequency, lead time for change, % emergency changes; request SLA performance; problem resolution cycle time and recurrence; CMDB accuracy; TMF CTA support tickets; interface error rates (EPCIS/E2B/MES–LIMS/CTMS–eTMF).
  • Compliance metrics: audit trail review completion, time sync/backup evidence adherence, access review completion; periodic review status; CAPA closure times.
  • FinOps: tagging for run/operate services, showback/chargeback by product/service, unit economics (cost per batch/test/site/user), forecast vs. actuals; vendor cost variances and service credit application.

Workstream 9: Tooling Enablement and Data Foundations

We configured tools to support the operating model.

  • ITSM: configured ServiceNow/Jira Service Management for processes, catalog, SLAs, and knowledge; integrated with IdP, monitoring/SIEM, CMDB discovery, ERP/MES/LIMS/CTMS where feasible; built workflow-based evidence capture.
  • CMDB: implemented auto-discovery (where possible) and integrations; established CI lifecycle and governance; mapped CIs to services for impact analysis.
  • Reporting: delivered dashboards and exports aligned to inspection and board reporting needs; implemented data lineage documentation.

Workstream 10: Change Management, Training, and Adoption

We enabled behavior change and sustainability.

  • Training: role-based curricula for service desk, app/platform teams, site OT/IT, Quality/CSV, vendor teams, and product owners; hands-on labs for incident/major incident, change/release, and DevSecOps pipelines; SOP/WI updates and quick reference guides.
  • Communications: service launch plan, performance reporting cadence, and recognition for SLA excellence and problem prevention; “no-surprises” policy for change scheduling and inspection readiness.

4) Data Request

We requested datasets and artifacts required to design and implement the IT operating model and service management for clients in the therapeutics spectrum. Typical horizons were 12–24 months historical and 12–36 months forward for plans and commitments.

  • Organization and governance:
    • Current IT/Quality org charts; RACI or role descriptions; CAB/CCB, ARB, and governance calendars; decision logs; escalation paths.
  • Process and tooling:
    • Existing ITSM process documentation and tool configs (incident, problem, change, release, request, knowledge, CMDB); runbooks; major incident postmortems; ticket volume/SLAs; knowledge articles.
  • Applications and integrations:
    • System inventory (ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, serialization/EPCIS, safety/E2B, data platforms); interface catalog and error logs; environment maps (dev/QA/prod); validation cadence and blackout windows.
  • Validation & compliance:
    • CSV/CSA policy, intended use/critical function statements, test evidence; Part 11/Annex 11 SOPs; audit/inspection findings; audit trail review logs; backup/restore and time sync evidence; periodic review schedules.
  • OT/IT:
    • Plant network diagrams and change windows; OT asset lists; incident history; MES–LIMS/historian/PLC connectivity details; recipe/method promotion practices.
  • Vendor management:
    • MSPs and SaaS providers; SOWs/SLAs; service credits/penalties; QBR decks; escalation contacts; performance reports; open issues and CAPAs.
  • Security and monitoring:
    • SIEM/monitoring coverage; EDR/XDR deployment; alert runbooks; vulnerability scanning scope and SLAs; IR playbooks; prior incidents.
  • Access and identity:
    • IdP/SSO/MFA coverage; RBAC/ABAC role catalogs; SoD matrices; JML workflows; quarterly access reviews and evidence packs.
  • Costs and capacity:
    • Run/operate budgets; ticket-driven time allocation; vendor spend; license metrics; staffing levels by function; overtime and contractor usage.
  • Milestones and constraints:
    • PPQ/CPV, trial startup, filing/launch dates; inspection schedules; plant shutdowns/maintenance; partner migrations or integrations.

Common data pitfalls included incomplete ticket categorizations and weak CMDB/CI mapping, missing intended use/critical function statements for validation, inconsistent audit trail review evidence, SoD gaps, vague SLAs/OLAs with vendors, missing interface ownership, plant change windows not recorded, and run/operate costs not tagged by service. We created a data dictionary, interface/CI ownership map, and version-controlled repository before design.

5) Questions for Client

  • Which milestones (IND/CTA, PoC, PPQ/CPV, BLA/MAA, launch) are most sensitive to service disruptions, and what uptime/latency targets are non-negotiable by system?
  • What service experience do your scientists, site operators, and clinical teams need (SLA/SLO, self-service, status transparency), and where are current pain points?
  • Which ITIL processes must be live in the next 60–90 days (incident/major incident, change, request), and which can phase later (problem, release, knowledge, CMDB)?
  • How should CAB/CCB and ARB interact with Quality and portfolio governance; what risk thresholds should trigger executive review?
  • What DevSecOps and SRE practices are acceptable under CSA; where will automated evidence satisfy validation?
  • Which catalog items and JML flows are highest priority (CTMS/eTMF access, ERP SoD roles, MES recipe, LIMS method, EPCIS/E2B verification)?
  • Which vendor relationships require SIAM coordination and KPI/QBR reset; what service credits/penalties and escalation levers are viable?
  • How should OT/IT segmentation and plant change windows be enforced; where are site-specific exceptions?
  • What compliance metrics and evidence must be surfaced monthly (audit trail review, periodic reviews, access certifications, backup/restore, change success rates)?
  • What dashboards and unit economics should executives and the board review (service KPIs, deployment frequency, % emergency changes, MTTR, FinOps by service)?

6) Interview Guide for Subject Matter Experts

Chief Information Officer / Head of IT

  • Which systems or processes most often trigger escalations; where does the operating model fail today?
  • How do you prioritize demand and balance run/operate with change initiatives; what governance gaps exist?
  • What tooling (ITSM/CMDB/monitoring) should be standardized; where is vendor integration most painful?

Head of Quality / CSV–CSA

  • Which evidence must ITSM capture for inspections (audit trails, e-signatures, backup/restore, periodic review)?
  • How should change enablement interact with validation; which standard changes can be pre-approved under CSA?
  • What CAPA linkages must exist from incidents/problems to eQMS?

Manufacturing OT / Site IT Lead

  • Where do incident runbooks and escalation paths break during shifts; what response times are realistic?
  • How should change windows and recipe/method promotion be controlled; where are MES–LIMS/historian bottlenecks?
  • What plant constraints (Purdue zoning, vendor access) must the operating model respect?

Clinical Systems Owner (CTMS/EDC/eTMF)

  • Which requests and incidents most affect startup and TMF CTA; what catalog items and SLAs are essential?
  • Where do integrations fail (CTMS–eTMF; EDC–CTMS); how should problem management and vendors engage?

ERP / Finance Systems Owner

  • What SoD conflicts recur; how should role requests be validated; what change controls are needed for close cycles?
  • Which incidents impact procure-to-pay and inventory accuracy; what metrics matter to Finance?

Data & Analytics Lead

  • Which data products (CPV, TMF CTA, program control) depend on timely incident resolution and change scheduling; how should lineage be enforced?
  • What service catalog items and SLAs support data platform requests and access control?

Security / Platform Engineering

  • How should SIEM/EDR detections route to ITSM; which automated runbooks are feasible; what evidence must be retained?
  • Where do pipelines, IaC, and change enablement conflict; what is the minimum viable gate model?

Vendor Management / Procurement

  • Which vendors underperform SLAs; what service credit and escalation models work; how should QBRs change?
  • Where do SOWs lack measurable outcomes; what changes will drive accountability?

7) Timeline

We executed a 12–14 week plan tailored to IT Operating Model & Service Management (ITIL, SLAs, DevSecOps, GxP) within Information Technology.

  • Weeks 1–2: Diagnostic & Blueprint
    • Assessed current org, processes, tooling, validation, vendor landscape, OT/IT constraints; mapped pain points to milestones; drafted operating model options and RACI.
    • Decision Gate A: Approved operating model blueprint, RACI, and prioritized ITIL processes; agreed governance charters (CAB/CCB, ARB) and quick-win backlog.
  • Weeks 3–4: Process Design & Catalog (MVP)
    • Authored SOPs/WIs for incident/major incident, change, request; configured ITSM (catalog items, SLAs/OLAs, queues); defined major incident runbooks; launched JML automation (pilot) and access review evidence packs.
    • Decision Gate B: Ratified process SOPs and catalog MVP; aligned SLAs/OLAs and escalation thresholds; approved pilot go-live.
  • Weeks 5–6: DevSecOps & CSA, CMDB & Knowledge
    • Implemented CI/CD guardrails and IaC patterns; documented CSA approach and automated validation artifacts; configured CMDB model and discovery; launched knowledge-centered support and initial runbooks.
    • Decision Gate C: Approved pipeline gates and CSA standards; validated CMDB scope; committed to SRE metrics (SLOs, error budgets).
  • Weeks 7–8: Vendor SIAM & OT/IT Support
    • Established SIAM roles, vendor QBR scorecards, escalation ladders; standardized plant incident paths, change windows, and recipe/method promotion controls; defined Purdue zoning guardrails in runbooks.
    • Decision Gate D: Confirmed SIAM model and QBR cadence; endorsed OT/IT support SOPs for rollout.
  • Weeks 9–10: Compliance-by-Design & Reporting
    • Embedded audit trail review, time sync, backup/restore, periodic review evidence into ITSM workflows; integrated eQMS CAPA linkage; delivered KPI dashboards and FinOps showback for run/operate services.
    • Decision Gate E: Cleared compliance evidence model; approved dashboards and reporting cadence.
  • Weeks 11–12: Pilot, Training & Handoff
    • Ran pilot with two domains (e.g., CTMS/eTMF and MES/LIMS); executed major incident drill; trained teams; refined SOPs; finalized governance; prepared inspection storyboards and board reporting pack.
    • Decision Gate F: Authorized scale; agreed 90–180 day backlog (problem/release management expansion, CMDB coverage, additional catalog items, deeper automation).
  • Weeks 13–14 (optional): Scale & Audit Readiness
    • Scaled catalog and SLAs to remaining domains; executed internal audit/inspection simulation; closed CAPAs; tuned DevSecOps gates and FinOps alerts.

Critical path items included agreement on RACI and governance charters, ITSM configuration bandwidth, Quality alignment on CSA and evidence capture, vendor participation in SIAM and QBRs, plant change windows, and readiness of monitoring data for SRE metrics.

8) Deliverables

  • Operating Model & RACI
    • Roles and responsibilities across IT, Quality, functional owners, and vendors; governance charters (CAB/CCB, ARB); escalation ladders; OT/IT support construct for plants.
  • ITIL Process SOPs & Runbooks
    • Incident/major incident, problem, change, release, request, knowledge, and configuration management SOPs/WIs; major incident and cutover runbooks tailored to ERP/MES/LIMS/QMS/CTMS/eTMF/serialization/E2B.
  • Service Catalog & SLA/OLA Pack
    • Catalog items with request models, SLAs/OLAs, SoD checks, and automated provisioning; communication templates, status pages, and fulfillment metrics.
  • DevSecOps & CSA Validation Toolkit
    • CI/CD gate patterns, IaC standards, automated evidence templates, validation summary report templates, and pipeline-to-change enablement integration.
  • CMDB & Knowledge Base Foundation
    • CI model, discovery/ownership, CI-to-service mapping; knowledge-centered support playbook; site-specific operational runbooks.
  • Vendor SIAM & QBR Scorecards
    • MSP/SaaS accountability framework; KPI scorecards; service credit/penalty models; escalation ladders; SOW redlines tying payments to evidence (e.g., interface tests, validation milestones).
  • Compliance by Design Evidence Model
    • Workflows, evidence artifacts, and inspection storyboards for audit trail review, e-signature, time sync, backup/restore, periodic review, and CAPA linkage; Part 11/Annex 11 mapping.
  • OT/IT Plant Support Playbook
    • Purdue zoning and micro-segmentation guidance; plant incident/major incident path; recipe/method promotion controls; maintenance and change windows; Quality sign-off checkpoints.
  • Dashboards & FinOps Reports
    • Service KPIs (MTTD/MTTR, change success rate, % emergency changes, deployment frequency, lead time for change, backlog aging), compliance metrics (audit trail, periodic review, access certification), interface error rates; showback/chargeback and unit economics.
  • Training & Adoption Kit
    • Role-based training materials, e-learning modules, SOP/WI updates, quick reference guides, and communications plan; adoption KPIs and continuous improvement cadence.

9) Industry Insights

  • ITIL v4 with SRE is the pragmatic blend for biotech
    • Biotech environments need steady-state reliability and fast change. ITIL v4 gives governance; SRE adds SLOs, error budgets, and automation to reduce toil while protecting IND/PoC/PPQ/filing windows.
  • CSA enables DevSecOps without compromising compliance
    • Risk-based validation focused on intended use and critical functions aligns automated pipelines with inspection-ready evidence. Pre-approved standard changes and pipeline-generated artifacts accelerate safe delivery.
  • Service catalogs must be domain-aware
    • Generic catalogs fail in GxP contexts. Items like “CTMS site onboarding,” “LIMS method setup,” and “MES recipe promotion” need SoD checks, evidence capture, and OLAs tailored to study and plant cadence.
  • SIAM is essential when vendors equal the team
    • Managed services and SaaS are the norm in biotech. A SIAM model with unified incident/major incident, change calendars, QBR scorecards, and service credits/penalties is needed to ensure accountability and speed.
  • OT/IT integration determines release reliability
    • Recipe/method and plant network changes must align to production cadence and validation windows. Purdue zoning, micro-segmentation, and clear site runbooks reduce downtime risk and inspection exposure.
  • Compliance must be embedded in service processes
    • Audit trail review, periodic review, access certifications, time sync, and backup/restore cannot be spreadsheet exercises. ITSM workflows should produce evidence packages the Quality team trusts.
  • Metrics and unit economics drive behavior
    • Change success, % emergency changes, deployment frequency, lead time for changes, MTTR, and interface error rates—paired with showback—create the transparency required for prioritization and vendor accountability.
  • What “good” looks like
    • Clear operating model and RACI; working ITIL v4 processes; domain-specific catalog and SLAs/OLAs; DevSecOps/SRE with CSA validation; SIAM vendor governance and QBRs; OT/IT plant support; compliance-by-design workflows; dashboards with unit economics; and trained teams executing consistently.
  • Near-term watch points
    • Alignment between IT and Quality on CSA and standard changes; legacy apps without SSO/automation; vendor cooperation for SIAM/QBRs; CMDB accuracy; plant change windows and segmentation; and adoption of SRE metrics. Quarterly governance health checks sustain momentum.

Implications for clients we served included enabling Emerging Therapeutic Biotech to stand up a right-sized ITSM and catalog before IND/IMPD; supporting Clinical-Stage Biotech to stabilize service and change control for PoC and PPQ/CPV; equipping Commercial Biotech to scale run/operate with SIAM, DevSecOps, and compliance-by-design through launch; guiding Platform Biotech to standardize operating models, catalogs, and vendor practices across partnered programs; and giving Biotech Investors & Incubators visibility into service risk, vendor performance, and compliance posture across portfolios.

Selected Capabilities of our Biotechnology Practice

Strategy & Corporate Development

  • Corporate Strategy And Growth Agenda: Define enterprise ambition, where to play and how to win, therapeutic area focus, build-partner-buy choices, and value creation roadmap for biotech platforms and asset-centric companies.
  • Portfolio Strategy And Indication Prioritization: Optimize pipeline across modalities using rNPV (risk-adjusted net present value), Probability of Technical and Regulatory Success, and constraints to prioritize indications, sequencing, and kill/hold decisions.
  • Business Development And Licensing Strategy: Set business development and licensing (BD&L) strategy, target screening, and out-licensing/in-licensing approach; shape deal thesis, valuation, and term sheets to maximize partnering value and optionality.
  • M&A Strategy And Diligence: Develop biotech mergers and acquisitions (M&A) strategy, longlist, shortlist, and theses; lead commercial, pipeline, and synergy diligence with integration blueprint and carve-out or asset-swap options.
  • Capital Allocation And Investor Readiness: Design capital allocation across programs and platforms; craft investor narrative, valuation, and financing strategy (venture, crossover, IPO) to extend runway and reduce cost of capital.

Operations

  • Manufacturing Operations Excellence: Improve yield, OEE, and right-first-time across upstream, downstream, and fill-finish to cut deviations, cycle time, and cost of goods for biologics and advanced therapies.
  • Tech Transfer And Scale-Up Execution: Plan and execute GMP tech transfer and scale-up, aligning control strategy and PPQ readiness to accelerate time-to-quality and de-risk commercial launch for new modalities.
  • Capacity Modeling And Debottlenecking: Model end-to-end capacity and cycle times, identify bottlenecks, and redesign schedules, changeovers, and cleanroom utilization to unlock throughput and defer capital for biotech facilities.
  • QC Release Cycle Time Reduction: Optimize QC labs with sampling rationalization, Laboratory Information Management System (LIMS), method lifecycle management, and scheduling to shorten batch release times and improve on-time-in-full service.
  • External Manufacturing Performance Management: Set governance with external manufacturing partners, KPIs, escalation, and issue resolution to improve on-time-in-full, right-first-time, and tech transfer outcomes while protecting supply.

Supply Chain

  • Integrated Business Planning And Supply Planning: Build integrated business planning with constrained supply planning and multi‑echelon inventory optimization to improve service, inventory turns, and adherence across drug substance and product networks.
  • Supply Network Design And Footprint Strategy: Optimize network of drug substance and drug product sites, distribution centers, and third‑party logistics to balance total landed cost, service, and risk in make‑buy‑location decisions.
  • Cold Chain And Temperature-Controlled Logistics: Design cold chain strategy, packaging, and lane qualification for 2–8°C, frozen, and cryogenic shipments; enable real‑time monitoring and excursion management to reduce spoilage and write‑offs.
  • Supply Risk And Shortage Management: Build multi‑tier risk mapping, dual‑sourcing strategies, and allocation playbooks with scenario planning and control‑tower alerts to prevent stockouts and manage biologics supply disruptions.
  • Cell And Gene Therapy Orchestration: Design vein‑to‑vein supply chain, chain of identity and custody, apheresis slot scheduling, and courier control to cut turnaround time and failure risk for autologous therapies.

Procurement & Strategic Sourcing

  • Category Strategy And Strategic Sourcing: Build category strategies for GMP raw materials, single-use assemblies, primary packaging; execute e-sourcing and negotiations to deliver Cost of Goods Sold (COGS) reduction and resiliency.
  • CDMO/CRO Vendor Selection And Contracting: Structure sourcing of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs); set Quality Agreements; negotiate capacity, pricing, and protections to de-risk delivery.
  • Should-Cost Modeling And Clean-Sheet Costing: Develop should-cost models for single-use assemblies, chromatography resins, media, vials, and contract services to set target prices and win fact-based negotiations.
  • Supplier Risk And Continuity Planning: Conduct supplier and tier-2 risk assessments for plasmids, viral vectors, resins; secure long-term agreements, dual-source contracts, and indexation clauses to ensure continuity and price stability.
  • Supplier Relationship Management And Governance: Establish segmentation, joint business plans, Quarterly Business Reviews (QBRs), Key Performance Indicators (KPIs), and innovation pipelines to improve on-time-in-full, quality, and access to new technologies.

R&D & CMC

  • CMC Strategy And IND Readiness: Define phase-appropriate CMC strategy, control plans, and dossier-ready packages to accelerate IND (Investigational New Drug) submissions and de-risk early clinical manufacturing.
  • Process Development And Characterization: Design and optimize upstream and downstream processes using Design of Experiments, scale-down models, and process characterization to achieve titer, purity, and robustness targets pre-transfer.
  • Analytical Development And Method Lifecycle: Build potency, purity, identity, and safety assays; qualify and validate methods; design stability programs to enable release, comparability, and control of critical quality attributes (CQAs).
  • Formulation And Drug Product Development: Develop phase-appropriate formulations, excipient strategies, and container-closure systems for biologics, mRNA, and viral vectors to improve stability, usability, and shelf life.
  • Comparability And Post-Change Strategy: Plan comparability protocols, risk assessments, and bridging analytics for process changes, site moves, or scale-up to protect product quality and avoid clinical rework.

Organization

  • Operating Model And Organizational Design: Design stage-appropriate biotech operating model across R&D, CMC, Clinical, Quality, Supply, and Commercial; align structure, decision rights, and governance to accelerate development and launch.
  • Leadership And Governance Effectiveness: Strengthen executive cadence, board interfaces, decision forums, and RACI (Responsible, Accountable, Consulted, Informed) clarity to speed decisions, resolve cross-functional issues, and drive accountability.
  • Talent Strategy And Workforce Planning: Build capability maps, workforce plans, and location strategy for bioinformatics, process development, regulatory, and commercial roles to meet milestones while optimizing cost and flexibility.
  • Ways Of Working And Agile Implementation: Implement agile teams in R&D and CMC, meeting redesign, OKRs (Objectives and Key Results), and collaboration norms to increase throughput, transparency, and reduce cycle time.
  • Scaling From Virtual To Commercial Organization: Plan build-out of Quality, Supply, and Commercial functions; define roles, spans and layers, and shared services to scale efficiently before first launch.

Marketing

  • Brand Strategy And Positioning: Define biotech brand narrative, target segments, value proposition, and messaging architecture to differentiate in rare and specialty indications and drive HCP and patient preference.
  • Omnichannel HCP Engagement And Content Operations: Design omnichannel journeys, modular content, and channel mix across email, rep-triggered, web, and social to increase HCP reach, engagement, and conversion within regulatory constraints.
  • Key Opinion Leader And Community Influencer Strategy: Map and activate key opinion leaders (KOLs), digital opinion leaders; co-create education, publications, and advisory forums to build credibility and accelerate guideline inclusion and adoption.
  • Launch And Prelaunch Excellence: Build evidence-driven launch plans, disease awareness, patient-finding, and HCP activation; sequence milestones, content, and congresses to maximize share of voice and first-year uptake.
  • Marketing Performance And ROI Analytics: Build dashboards, marketing-mix models, and experimentation to attribute impact, optimize spend, and improve return on investment (ROI) across HCP, patient, and digital channels.

Pricing

  • Launch Pricing And Price Corridor Design: Define Wholesale Acquisition Cost (WAC) and ex-US list prices, price corridors, and price-volume curves by indication to balance access, uptake, and lifetime revenue.
  • Gross-To-Net Optimization: Diagnose rebate, chargeback, copay, 340B Drug Pricing Program (340B), Medicaid Best Price leakages; design contracting, accruals, and governance to improve net price and predictability.
  • Outcomes-Based And Innovative Contracting: Structure outcomes-based contracts, annuity payments, and warranties for gene and cell therapies; define metrics, data flows, and risk-sharing to secure access and net revenue.
  • International Reference Pricing And Launch Sequencing: Model cross-border reference rules, parallel trade, and price spillover; optimize country sequencing, tender posture, and corridors to protect global net price.
  • IRA And Price Renegotiation Readiness: Build Inflation Reduction Act (IRA) strategy, revenue risk scenarios, and negotiation playbooks; adjust contracting, launch timing, and portfolio mix to mitigate price erosion.

Sales

  • Field Force Sizing And Territory Design: Optimize field force size, territories, Customer Relationship Management (CRM) call plans, and routing to maximize healthcare professional (HCP) coverage and productivity for biotech specialty therapeutics.
  • Key Account Management Enablement: Establish Key Account Management (KAM) model for Integrated Delivery Networks (IDNs) and centers of excellence with planning, access pull-through, and cross-functional engagement to drive adoption.
  • Incentive Compensation And Sales Performance Management: Design compliant incentive plans, quotas, and scorecards; align to new patient starts, persistency, and access status to drive specialty biotech revenue growth.
  • Specialty Pharmacy And Hub Pull-Through: Orchestrate specialty pharmacy and patient support hub processes to reduce time-to-fill, improve benefits verification, and increase therapy initiation and adherence for complex treatments.
  • Sales Training And Field Readiness: Develop disease-state and clinical selling curricula, objection handling, and certification; equip field teams with compliant materials and tools to accelerate launch uptake and competitive wins.

Finance

  • FP&A And Runway Management: Build integrated cash, P&L, and scenario models; align to milestones and business development (BD) events; enable rolling forecasts to extend runway and optimize burn.
  • Product Costing And COGS Transparency: Establish standard costing, variance tracking, lot-level analytics, and transfer pricing to improve Cost of Goods Sold (COGS) predictability and margin decisions for biologics.
  • Working Capital Optimization: Optimize inventory policies, supplier terms, and collaboration cash schedules; redesign milestone invoicing to improve cash conversion cycle and fund critical programs.
  • Record To Report And Fast Close: Redesign close processes, chart of accounts, and Sarbanes-Oxley (SOX) controls to enable accurate inventory valuation, capitalization, and fast, audit-ready closes.
  • Collaboration And Revenue Recognition Advisory: Interpret Accounting Standards Codification (ASC) 606 for licenses, milestones, and cost-sharing; design policies, accruals, and systems to ensure compliant, audit-ready biotech revenue recognition and disclosures.

AI, Data & Analytics

  • Biotech Data Platform And Governance: Build FAIR, GxP-compliant data platforms with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity.
  • CMC Digital Twins And Process AI: Develop bioprocess digital twins, multivariate control, and soft sensors to predict critical quality attributes, boost yield, and reduce deviations, cycle time, and cost.
  • Generative AI Copilots For CMC And Quality: Deploy large language models (LLMs) with Retrieval-Augmented Generation (RAG) for authoring, querying, and change-impact analysis; ensure validation, permissions, and audit trails in regulated environments.
  • RWE And Clinical AI For Trial Acceleration: Build real-world evidence pipelines and machine learning for patient finding, eligibility inference, and site selection to accelerate enrollment and improve protocol feasibility.
  • MLOps And Model Risk Management: Establish data pipelines, feature stores, versioning, monitoring, and validation with model risk controls and change management to safely scale AI in GxP settings.

Transformation

GxP Quality & Compliance

  • Quality Management System Design And Maturity Uplift: Design risk-based QMS aligned to ICH Q10; optimize SOPs, governance, roles, and metrics to meet GMP/GLP/GCP expectations and accelerate approvals and batch release.
  • Inspection Readiness And Remediation: Run risk-based inspection readiness with mock audits, storyboards, SME coaching, and day-in-the-life war rooms; lead remediation and CAPA plans to close FDA/EMA observations.
  • Data Integrity And Computerized Systems Assurance: Assess ALCOA+ data integrity, remediate gaps, and implement risk-based Computer Software Assurance; validate eQMS, LIMS, MES, and analytics with lifecycle controls and audit trails.
  • Deviation CAPA And Change Control Excellence: Redesign deviation, root cause analysis, CAPA effectiveness, and change control workflows; implement analytics and right-first-time behaviors to reduce recurrence, cycle time, and compliance risk.
  • External Partner Quality Oversight And Audits: Establish risk-based oversight for CDMOs, CROs, and suppliers; set Quality Agreements, audit programs, and release-by-exception to strengthen compliance, tech transfer outcomes, and supply reliability.

Program & Portfolio Management

Information Technology

  • IT Strategy And Enterprise Architecture: Define IT strategy, target architecture, and systems roadmap across ERP, MES, LIMS, QMS, CTMS, and EDC to enable scale, compliance, and faster launch readiness.
  • Core Systems Selection And Implementation Readiness: Run vendor selection for ERP, Veeva Vault Quality/Regulatory, MES, LIMS, and CTMS; define requirements, integrations, and implementation governance to de-risk delivery.
  • Cloud And Infrastructure Modernization: Design secure, GxP-ready cloud architecture on AWS or Azure, with network standards and disaster recovery, improving agility, reliability, and cost transparency.
  • Cybersecurity And Identity Management: Build cybersecurity program with risk-based controls, identity and access management, privileged access, and OT segmentation to protect patient data, intellectual property, and manufacturing assets.
  • IT Operating Model And Service Management: Design IT operating model, ITIL processes, and service catalog; establish SLAs, DevSecOps, and vendor management to improve service quality, delivery speed, and compliance.

Regulatory Affairs

  • Global Regulatory Strategy And Agency Engagement: Define IND/CTA-to-BLA/MAA strategy, pursue orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and PRIME designations, and lead health authority interactions to de-risk development and approvals.
  • Submission Planning And eCTD Readiness: Build submission roadmap, authoring plan, Module 2/3 strategy, vendor/publisher governance, and quality checks to deliver first-cycle, on-time eCTD submissions across regions.
  • Labeling Strategy And Negotiation: Align Target Product Profile, evidence, and claims; lead core data sheet, USPI/SmPC development, negotiation strategies, and CCDS governance to secure competitive labels.
  • Post-Approval Lifecycle And Variations Management: Design regulatory pathways for post-approval changes; prepare supplements and variations, manage commitments, and harmonize dossiers to sustain global compliance and supply continuity.
  • Companion Diagnostic And Combination Product Regulatory Strategy: Define CDx co-development and combination product strategy, classification, and submission pathways; coordinate interactions with FDA device and drug centers to synchronize approvals and enable precision therapy access.

Clinical Development & Operations

  • Protocol Design And Operational Feasibility: Optimize protocol endpoints, eligibility, visit schedules, and assessments using feasibility and real-world data to cut screen failure, patient burden, cost, and cycle time.
  • Country And Site Strategy: Use epidemiology, investigator performance, and startup cycle time data to select countries and sites, set allocations, and build contingency to achieve predictable enrollment.
  • Patient Recruitment And Retention Acceleration: Deploy patient finding, referral networks, decentralized visits, eConsent, diversity plans, and travel support to accelerate enrollment, cut discontinuations, and improve last patient out predictability.
  • Risk Based Quality Management And Monitoring Optimization: Implement risk based quality management per Good Clinical Practice, central monitoring, tolerance limits, and source verification to lower queries, deviations, and monitoring cost.
  • CRO Oversight And Performance Management: Establish sponsor oversight aligned to Good Clinical Practice with KPIs, tolerance limits, issue escalation, and corrective action governance to improve CRO on-time delivery and quality.

Market Access & HEOR

  • Payer Value Proposition And Access Strategy: Define payer value proposition, unmet need, comparators, and access milestones; shape P&T and prior authorization criteria to secure rapid, broad coverage for specialty biologics.
  • Global HTA Strategy And Dossier Development: Develop global value dossier and AMCP dossier; plan NICE, G-BA, SMC, HAS submissions; tailor evidence and narratives to achieve first-cycle HTA approvals.
  • Health Economic Modeling And Evidence Synthesis: Build cost-effectiveness and budget impact models, partitioned survival or Markov; conduct indirect treatment comparisons and network meta-analyses to meet HTA and payer requirements.
  • Real-World Evidence For Value Demonstration: Design RWE strategy including registries, external control arms, and burden-of-illness studies; generate endpoints and PROs supporting HTA, ICER reviews, label expansions, and reimbursement renewals.
  • Coding Coverage And Reimbursement Strategy: Establish coding pathways, HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics to secure coverage, appropriate payment, and patient affordability across channels.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]